Fulranumab
Fulranumab
Fulranumab (pronounced: /fʊlˈrænʊmæb/) is a monoclonal antibody that was under development for the treatment of chronic pain conditions. It was developed by Janssen Biotech, a pharmaceutical company that is a subsidiary of Johnson & Johnson.
Etymology
The name "Fulranumab" is derived from the Latin words "ful" meaning "full", "ran" meaning "to run", and "umab" which is a common suffix for monoclonal antibodies.
Mechanism of Action
Fulranumab works by targeting and inhibiting the nerve growth factor (NGF), a protein that plays a key role in the growth and survival of nerve cells. By blocking NGF, Fulranumab can potentially reduce pain signals sent by damaged or inflamed tissues.
Clinical Trials
Fulranumab has undergone several clinical trials to evaluate its safety and efficacy in treating various chronic pain conditions, including osteoarthritis, neuropathic pain, and cancer pain. However, the development of Fulranumab was discontinued in 2016 due to business reasons.
Related Terms
- Monoclonal antibody
- Chronic pain
- Nerve growth factor
- Clinical trial
- Osteoarthritis
- Neuropathic pain
- Cancer pain
External links
- Medical encyclopedia article on Fulranumab
- Wikipedia's article - Fulranumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski